International Journal of Hepatology
https://www.banglajol.info/index.php/IJH
<p><span style="color: #221e1f;"><span style="color: #221e1f;">As far as we are aware, this journal is no longer being published.<br /></span></span></p><p><span style="color: #221e1f;"><span style="color: #221e1f;">Official Journal of Viral Hepatitis Foundation Bangladesh. <br />Formerly the <em>Bangladesh Liver Journal</em>. Full text articles available.<br /></span></span></p>Viral Hepatitis Foundation of Bangladeshen-USInternational Journal of HepatologyAssociation between non-alcoholic fatty liver disease and metabolic syndrome
https://www.banglajol.info/index.php/IJH/article/view/6571
Metabolic syndrome describes the co-occurrence of central adiposity, dysglycaemia, hypertension, lipid abnormalities and a number of other metabolic changes that increase risk of cardiovascular disease. This multi-system condition has adverse effects on many organs, the liver being one of them. Non-alcoholic fatty liver disease appears to be the hepatic manifestation of metabolic syndrome, and is increasingly recognised as a major contributor to the burden of chronic liver disease world-wide. Metabolic syndrome and non-alcoholic fatty liver disease appear to have a common pathogenesis, arising from insulin resistance, central adiposity and chronic low grade inflammation. Treatment of metabolic syndrome may have a significant impact on progression of non-alcoholic fatty liver disease, and therapeutic options treating the underlying cause of metabolic syndrome (weight loss and insulin sensitising drug therapy) appear to be valid options in treating liver disease to prevent progression to fibrosis and cirrhosis. Recent studies suggest a possible role for vitamin E. Prevention of obesity is extremely important to reduce the risk of this condition leading to a growing cause of liver morbidity in the future. <br /><br /><strong>Keywords: </strong>Non-alcoholic steatohepatitis; non-alcoholic fatty liver disease; metabolic syndrome <br /><br /><em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.17-24Rasheeta SivapackianathanArthur J AsivathamMamun Al-MahtabTahseen A Chowdhury
Copyright (c)
141724Current and emerging treatments for cholangiocarcinoma
https://www.banglajol.info/index.php/IJH/article/view/6572
Surgical resection, the treatment of choice for cholangiocarcinoma, may not be feasible because of tumour extension, parenchymal liver disease or tumour location. Liver transplantation is an alternative to palliative treatment in these patients but results in the past have been disappointing. In this article, we review the current and emerging treatments for cholangiocarcinomas, focusing particularly on the role of neoadjuvant chemotherapy and/ or radiotherapy in the setting of liver transplantation. <br /><br /><strong>Keywords:</strong> Cholangiocarcinoma; biliary tract neoplasms; living donor liver transplantation; cadaveric donor liver transplantation. <br /><br /><em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.25-35Christopher LimDesmond WaiKH LeeKC Tan
Copyright (c)
142535LIVERCON 2010 at a Glance
https://www.banglajol.info/index.php/IJH/article/view/6569
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.8-12The Editor
Copyright (c)
14812LIVERCON 2010: Abstracts
https://www.banglajol.info/index.php/IJH/article/view/6570
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.13-16The Editor
Copyright (c)
141316Management of recurrent bleeding from facial arteriovenous malformations in end-stage liver disease
https://www.banglajol.info/index.php/IJH/article/view/6577
We report the management by arterial embolisation of recurrent significant bleeding from a facial arteriovenous malformation (AVM) in a patient with end-stage liver disease. Given their propensity to re-bleed, AVMs are often refractory to other forms of treatment, including surgery. Evidence from the management of facial AVMs and our case suggests that embolisation may offer a better initial management strategy in patients with end-stage liver disease related facial AVMs. <br /><br /><em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.53-54Syed Sufyan HussainKuldeep S CheentShahid A KhanJames E JacksonMary ME CrosseyHoward C ThomasSimon D Taylor Robinson
Copyright (c)
145354Hepatitis C in Pakistan- A neglected challenge
https://www.banglajol.info/index.php/IJH/article/view/6568
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.5-7Waris QidwaiAmmad FahimShahan Waheed
Copyright (c)
1457Hepatitis C - Goals of therapy and monitoring of therapy
https://www.banglajol.info/index.php/IJH/article/view/6573
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.36-44Premashis KarRajib Kishore Hazam
Copyright (c)
143644NAFLD current concepts
https://www.banglajol.info/index.php/IJH/article/view/6574
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.45-49Deepak Amarapurkar
Copyright (c)
144549Rationality and designing immune therapy against chronic hepatitis B virus infection
https://www.banglajol.info/index.php/IJH/article/view/6575
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.49-50Sheikh Mohammad Fazle AkbarMamun Al-MahtabSakirul Islam Khan
Copyright (c)
144950Fibroscan: Non-invasive liver diagnostic device for detection of liver fibrosis
https://www.banglajol.info/index.php/IJH/article/view/6576
<em>International Journal of Hepatology</em> Vol.1(4) 2010 pp.50-52Grace Lai-Hung Wong
Copyright (c)
145052